Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323335 · ClinicalTrials.gov registry record · Phase 1
The Relationship Between Uric Acid and Inflammatory Markers
A Phase 1 study of Healthy Volunteers, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT01323335 is a Phase 1 study of Healthy Volunteers that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 97 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01323335, a Phase 1 study of Healthy Volunteers, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Uric acid is a substance found in the blood that may contribute to certain chronic medical conditions and disorders, such as diabetes, insulin resistance, and high blood pressure. High uric acid concentrations have been associated with stroke and heart disease, as well as chronic heart failure. In particular, researchers are interested in determining the relationship between uric acid and inflammatory markers, or chemicals in the blood that can indicate inflammation and other problems with the body. Objectives: * To study the specific effects of changes in uric acid in the body. * To determine whether uric acid contributes to inflammation in the body. Eligibility: \- Healthy individuals between 50 and 75 years of age. Design: * This study will involve four visits: a screening visit, two study visits, and a followup visit. * At the screening visit, participants will have a physical examination, blood and urine tests, and an electrocardiogram. Participants will be divided into two groups based on the existing amount of uric acid in their blood. * Within 7 days of the screening visit, participants will have a full-day study visit with a magnetic resonance imaging scan, followed by a high-fat meal and further blood samples collected over the following 8 hours. * At least 2 days after the first study visit, participants will have the second study visit, which will require a 2-night stay at the National Institutes of Health. Participants will have a metabolism test, and will receive the following infusions based on the groups they were assigned to at the screening visit. * Group A (low uric acid) will receive either uric acid or a placebo. * Group B (moderate to high uric acid) will receive either Rasburicase (a drug that reduces the amount of uric acid in the blood) or a placebo. * After the infusions and related blood tests, participants will have a high-fat meal with further blood and urine samples. * Approximately 2 weeks after the second study v
Conditions Studied
Interventions
- DRUG IV Uric Acid
- DRUG IV Rasburicase
Study Locations (1)
Maryland
- National Institute of Aging, Clinical Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2009-03-31 |
| Est. Completion | 2014-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01323335
The ClinicalTrials.gov registry entry for NCT01323335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (80% lower). The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which IV Uric Acid is the first listed.
NCT01323335 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01323335 about?
NCT01323335 is a clinical study titled "The Relationship Between Uric Acid and Inflammatory Markers". Background: \- Uric acid is a substance found in the blood that may contribute to certain chronic medical conditions and disorders, such as diabetes, insulin resistance, and high blood pressure. High uric acid concentrations have been associated with stroke and heart disease, as well as chronic hea...
What is the current status of trial NCT01323335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2009-03-31. Estimated completion is 2014-01-31.
What conditions does trial NCT01323335 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT01323335?
The interventions under investigation include: IV Uric Acid (DRUG), IV Rasburicase (DRUG).
Who is sponsoring clinical trial NCT01323335?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01323335 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.